Name of Policy:	**Management of Critical INR Values**	
Policy Number:	3364-133-114	
Department:	Pharmacy	
Approving Officer:	Chief Executive Officer	
Responsible Agent:	Senior Hospital Administrator	
Scope:	University of Toledo Medical Center	**Effective Date**: 7/31/2022 **Initial date:** 4/1/2016

	New policy proposal		Minor/technical revision of existing policy
	Major revision of existing policy	**X**	Reaffirmation of existing policy

(A) Policy Statement:

    a.   The University of Toledo Anticoagulation Clinic staff will follow the outlined steps in managing critical INR values protocol

(B) Purpose of Policy:

    a.   The purpose of this policy is to provide guidance in management of critical INRs above 5 and warfarin reversals. Pharmacists and staff will use American College of Chest guidelines for managing critical INRs greater than 5 and if patient needs to be admitted in the hospital for acute management

(C) Procedure:

    a.   Critical INRs greater than 5 will be handled within 24 business hours of receiving the results using recommendations of CHEST Guidelines as outlined below for clinical guidance

    b.   After hours critical INRs will be managed by on call pharmacy residents or pharmacy staff within 24 business hours of receiving the results using recommendations of CHEST Guidelines as outlined below for clinical guidance.

    c.   Any clinically significant bleeding should be communicated to the referring physician.

    d.   All actions will be documented in patient's EMR

Clinical Scenario	Treatment of Elevated INR	Time to Recheck INR
No clinically significant bleeding, no urgent/emergent surgery/procedure		
INR 5.0-9.9	Omit 1-2 doses of warfarin. Resume at lower dose when INR therapeutic.	24-48 Hours
INR >9.9	Omit 1-2 doses of warfarin. Consider Vitamin K 2.5mg PO x 1, Resume at lower dose when INR therapeutic. May refer patient to nearest emergency department for evaluation under clinic discretion.	24-48 Hours
Clinically significant bleeding		
Any INR	Refer patient to nearest emergency department for evaluation.	

Approved by:		**Review/Revision Date:** 4/2018 7/2019 6/2022
/s/ _____ Russell Smith, PharmD, MBA, BCPS Senior Hospital Administrator	06/27/2022 Date	
/s/ _____ Rick Swaine Chief Executive Officer	07/11/2022 Date	
/s/ _____ Samer Khouri, MD, MBA Medical Director, Anticoagulation Clinic	08/03/2022 Date	
		Next Review Date: 7/1/2025